About: Recommendations for sample pooling on the Cepheid GeneXpert® system using the Cepheid Xpert® Xpress SARS-CoV-2 assay

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Recommendations for sample pooling on the Cepheid GeneXpert® system using the Cepheid Xpert® Xpress SARS-CoV-2 assay Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Recommendations for sample pooling on the Cepheid GeneXpert® system using the Cepheid Xpert® Xpress SARS-CoV-2 assay
Creator	Sandstrom, Paul Taylor, Tracy Becker, Michael Cabiles, Dana Kiazyk, Sandra Meyers, Adrienne
Source	BioRxiv
abstract	The coronavirus disease 2019 (Covid-19) pandemic, caused by SARS-CoV-2, has resulted in a global testing supply shortage. In response, pooled testing has emerged as a promising strategy that can immediately increase testing capacity. Here, we provide support for the adoption of sample pooling with the point-of-care Cepheid Xpert® Xpress SARS-CoV-2 molecular assay. Corroborating previous findings, the Xpert® Xpress SARS-CoV-2 assay limit of detection was comparable to central laboratory reverse-transcription quantitative PCR tests with observed SARS-CoV-2 detection below 100 copies/mL. The Xpert® Xpress assay detected SARS-CoV-2 after samples with minimum viral loads of 461 copies/mL were diluted into six sample pools. Based on these data, we recommend the adoption of pooled testing with the Xpert® Xpress SARS-CoV-2 assay where warranted by population public health needs. The suggested number of samples per pool, or pooling depth, is unique for each point-of-care test site and should be determined by assessing positive test rates. To statistically determine appropriate pooling depth, we have calculated the pooling efficiency for numerous combinations of pool sizes and test rates. This information is included as a supplemental dataset that we encourage public health authorities to use as a guide to make recommendations that will maximize testing capacity and resource conservation.
has issue date	2020-07-15(xsd:dateTime)
bibo:doi	10.1101/2020.05.14.097287
has license	biorxiv
sha1sum (hex)	26dc82b70f4c81b144bee1d191db41eb932333b3
schema:url	https://doi.org/10.1101/2020.05.14.097287
resource representing a document's title	Recommendations for sample pooling on the Cepheid GeneXpert® system using the Cepheid Xpert® Xpress SARS-CoV-2 assay
schema:publication	bioRxiv
resource representing a document's body	covid:26dc82b70f4c81b144bee1d191db41eb932333b3#body_text
is schema:about of	named entity 'number' named entity 'caused' named entity 'Cepheid' named entity 'sizes' named entity 'MOLECULAR ASSAY' covid:arg/26dc82b70f4c81b144bee1d191db41eb932333b3 named entity 'adoption' named entity 'determined' named entity 'SARS-CoV-2' named entity 'Xpress' named entity 'response' named entity 'coronavirus disease 2019' named entity 'laboratory' named entity 'population' named entity 'efficiency' named entity 'strategy' named entity 'SARS-CoV-2' named entity 'coronavirus disease 2019' named entity 'Cepheid' named entity 'SARS-CoV-2' named entity 'point-of-care' named entity 'GeneXpert' named entity 'SARS-CoV-2' named entity 'bioRxiv' named entity 'positive test' named entity 'RT-qPCR' named entity 'nucleocapsid' named entity 'bioRxiv' named entity 'point-of-care tests' named entity 'negative result' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'preprint' named entity 'point-of-care tests' named entity 'SARS-CoV-2' named entity 'pipettes' named entity 'point-of-care testing' named entity 'CC-BY 4.0 International license' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'viral load' named entity 'linear equation' named entity 'SARS-CoV-2' named entity 'CC-BY 4.0 International license' named entity 'preprint' named entity 'LOD' named entity 'bioRxiv' named entity 'preprint' named entity 'GeneXpert' named entity 'SARS-CoV-2' named entity 'peer review' named entity 'medRxiv' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'Public health' named entity 'coronavirus disease 2019' named entity 'blood donor' named entity 'preprint' named entity 'Health Canada' named entity 'SARS-CoV-2' named entity 'RNA' named entity 'positive test' named entity 'disease prevalence' named entity 'SARS-CoV-2' named entity 'preprint' named entity 'reverse transcription PCR' named entity 'SARS-CoV-2' named entity 'pipettes' named entity 'SARS-CoV-2' named entity 'genome' named entity 'SARS' named entity 'preprint' named entity 'peer review' named entity 'CC-BY 4.0 International license' named entity 'positive test' named entity 'preprint' named entity 'standard curve' named entity 'SARS-CoV-2' named entity 'preprint'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software